Luminex Plc · CSELK:LUMX.N0000
Luminex — JP Morgan Healthcare Conference 2019
26 slides from Luminex's conference presentation, Jan 7, 2019
Slide 1: JP Morgan Healthcare Conference Investor Presentation
JP Morgan Healthcare Conference Investor Presentation Nachum “Homi” Shamir President and Chief Executive Officer January 9, 2019 CONFIDENTIAL
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain statements made during the course of this presentation may not be purely historical and consequently may be forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements made regarding: our
Slide 3: Preliminary Q4 and 2018 Revenue
Preliminary Q4 and 2018 Revenue Fourth quarter Full year 2018 revenue ~$81M 2018 revenue >$315M • Total LTG revenue of over $41M, up 23% • Total LTG revenue of $149M, up 5% vs. the fourth quarter of 2017 vs. the full year 2017 • Total MDx revenue of ~$39M, a decline of • Total MDx revenue of ~$164M,
Slide 4: Introduction
Introduction Molecular Diagnostics Group (MDx) Licensed Technologies Group (LTG) Flow Cytometry (IRIS) complexity simplified. | © Copyright 2019 Luminex Corporation CONFIDENTIAL 4
Slide 5: Luminex: A Diversified Business
Luminex: A Diversified Business LICENSED MOLECULAR TECHNOLOGIES DIAGNOSTICS GROUP S2A Revenue Growth Annual Growth 41% Mid-Single Digits 2018 MDx Revenue 2018 Related Revenue ~$164M $149M Active Direct Customers Instruments Sold by 70+ Partners ~600 ~16,000 complexity simplified. | © Copyright 2019
Slide 6: Luminex: Our Future Together
Luminex: Our Future Together LICENSED MOLECULAR FLOW TECHNOLOGIES CYTOMETRY DIAGNOSTICS GROUP S2A Revenue Growth Annual Growth Annual Growth 41% Mid-Single Digits High-Single Digits 2018 MDx Revenue 2018 Related Revenue 2018 Related Revenue ~$164M $149M ~$40M Active Direct Customers Instruments Sold
Slide 7: Molecular Diagnostics
Molecular Diagnostics
Slide 8: Quarterly S2A MDx Revenue
Quarterly S2A MDx Revenue* On Track to Achieve ~$100M >260 Run-Rate Target by YE19 VERIGENE® and ~$25M ARIES® Systems placed under contract in $18M 2018 $13M $10M $7M Entire VERIGENE® and ARIES® 4Q15 4Q16 4Q17 4Q18 4Q19E infectious disease test menu driving growth complexity simplified. | © Copyrigh
Slide 9: Sample to Answer (S2A)
Sample to Answer (S2A) VERIGENE® ARIES® Active ~600 $100,000 $55,000 Customers Avg Annual Revenue/ Avg Annual Revenue/ Active Customer* Active Customer* Syndromic Assays: Targeted Assays: BC-GN, BC-GP, Bordetella, C. diff, 360 EP, RP Flex Flu A/B/RSV, GAS, GBS, HSV 1&2, LDTs, MRSA (2019) 1Q17 4Q18 c
Slide 10: VERIGENE Systems Comparison
VERIGENE® Systems Comparison ® ® Key Characteristics: VERIGENE I VERIGENE II Chemistry Nanoparticles Nanoparticles Consumables 4 1 Shipping/Storage Refrigerator/Freezer Ambient Storage Automation Level Manual Set-up and Transfer to Reader Fully Automated, Sample to Result Throughput per System 1 Fle
Slide 11: Consolidation of Molecular Sample to Answer Testing
Consolidation of Molecular Sample to Answer Testing Integrated Cartridge Testing Evolution - Combining the Best of Both Worlds • S2A for targeted assays ® VERIGENE® II Plus • Random batch • 2-hour TAT ARIES • LDT open channel option • Fast TAT • Quantification (e.g. viral load monitoring) • Menu con
Slide 12: Reimbursement Updates
Reimbursement Updates • Palmetto has changed its guidance on syndromic assay testing • Multiple Medicare Administrative Contractors Flex (MACs) expected to adopt the MolDx guidance Testing is • Some private payers have already issued the Path medical policy to explicitly cover panels Forward • Allow
Slide 13: How We Win: Total Portfolio Selling
How We Win: Total Portfolio Selling Breadth of Solutions Superior Economic Value The Result • Platform ease of use; • Luminex well- • ~600 customers and throughput options positioned for shifting growing • Breadth of menu: reimbursement • MDx S2A revenue targeted and • Breadth/flexibility of $62M in
Slide 14: Licensed Technologies Group
Licensed Technologies Group
Slide 15: Licensed Technologies Group: Overview
Licensed Technologies Group: Overview Total Cumulative xMAP® LTG-Related Revenue, % of Total LTG-Related LTG: Systems Sold to Date* by Product Revenue, by Market >45% 16,000 of Total 14,900 Revenue 12,700 13% 32% 40% 40% 10,700 22% Mid- 33% Single 8,700 20% Digit Growth Long-Term 2011 2013 2015 2017
Slide 16: Licensed Technologies Group: Overview
Licensed Technologies Group: Overview $350 Total Revenue* $1,200 Reported End-user Sales* $300 $1,000 $250 $800 $200 $600 $150 $400 $100 (Millions) (Millions) $50 $200 $- $- '03/'04 '05/'06 '07/'08 '09/'10 '11/'12 '13/'14 '15/'16 '17/'18 '03/'04 '05/'06 '07/'08 '09/'10 '11/'12 '13/'14 '15/'16 '17/'1
Slide 17: Introducing the Newest Member of the xMAP System Family
Introducing the Newest Member of the xMAP® System Family Modern enhancements for the gold standard multiplexing platform ® SENSIPLEX™ System • 500-plex • 20 min read time • Full xMAP backwards- FLEXMAP 3D compatibility • Increased sensitivity & dynamic range 200 ™ ® • 100-plex • Improved automation
Slide 18: Licensed Technologies Group: Key Takeaways
Licensed Technologies Group: Key Takeaways • 70+ partners investing in our technology; addressing large markets • Long-term contractual partnerships • Stable growth; highly profitable • Large and growing system base • SENSIPLEX™ on the horizon complexity simplified. | © Copyright 2019 Luminex Corpor
Slide 19: Flow Cytometry
Flow Cytometry
Slide 20: Flow Cytometry strengths
Strong financial outlook High quality differentiated Flow based on successful redesign flow cytometers with Cytometry and promising R&D pipeline strong brand recognition Strengths Strong R&D team Attractive growth focused on innovation market categories, & new product supported by development in str
Slide 21: Portfolio: Balance of Performance and Affordability
Portfolio: Balance of Performance and Affordability ® FlowSight ImageStream®X Cell Function & Mark II Mechanism Imaging FC Unique offering; combines high resolution imaging with flow cytometry easyCyte™ CellStream® easyCyte™ HT Advanced Phenotyping Phenotyping & Analysis Performance Muse® Analysis C
Slide 22: Product Roadmap 2019
Product Roadmap 2019 Advanced Development for Existing Platforms Amnis® 21CFR IDEAS® Automated Muse® Software Guava® IDEAS Deep part 11 Enabled Classification Malaria RUO Module Designer Next Gen Learning Module Software Module Malaria bead- Enable rapid User logging and Simplify Amnis COG
Slide 23: Financial Overview and Summary
Financial Overview and Summary
Slide 24: 2019 Guidance
2019 Guidance Fourth quarter Full year 2018 revenue ~$81M 2018 revenue >$315M • Less LabCorp $35M • LTG flat to slight decline 2019 $337M – guidance: • Total MDx growth ~15% $343M - S2A 35% growth • Flow cytometry to add ~$45M complexity simplified. | © Copyright 2019 Luminex Corporation CONFIDENTIA
Slide 25: Summary
Summary Molecular Diagnostics Group (MDx) Licensed Technologies Group (LTG) Flow Cytometry (IRIS) complexity simplified. | © Copyright 2019 Luminex Corporation CONFIDENTIAL 25
Slide 26: Thank You
Thank You Luminex. complexity simplified. <P . =a